U2 Total Knee System Tibial Insert, PSA, #1, 21mm Thick Catalogue number 2303-5016 The U2 Tota...

FDA Device Recall #Z-1129-2018 — Class II — November 24, 2017

Recall Summary

Recall Number Z-1129-2018
Classification Class II — Moderate risk
Date Initiated November 24, 2017
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm United Orthopedic Corporation
Location Hsinchu, N/A
Product Type Devices
Quantity 14 pieces

Product Description

U2 Total Knee System Tibial Insert, PSA, #1, 21mm Thick Catalogue number 2303-5016 The U2 Total Knee system is indicated in knee arthroplasty for reduction or relief of pain and/or improved knee function in skeletally mature patients with severe knee pain and disability due to rheumatoid arthritis, osteoarthritis, primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyle or pseudogout, posttraumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy, moderate valgus, varus, or flexion deformities. This device may also be indicated in the salvage of previously failed surgical attempts if the knee cannot be satisfactorily balanced and stabilized at the time of surgery.

Reason for Recall

UOC received a customer compliant report from our distributor on October 31, 2017 which stated that contents of the package do not match the product labeling.

Distribution Pattern

Worldwide Distribution - US Distribution and to the countries of: UK, Iran, Greece, Pakistan, Switzerland, France, China, Taiwan, Italy, Korea and South Africa.

Lot / Code Information

Lot number 17B621AG

Other Recalls from United Orthopedic Corporation

Recall # Classification Product Date
Z-1217-2024 Class II USTAR II Knee System : Cemented Curved Stem, RH... Jan 3, 2024
Z-1215-2024 Class II USTAR II Hip System Press-Fit Curved Stem, RHS ... Jan 3, 2024
Z-1216-2024 Class II USTAR II Knee System Cemented curved stem, RHS,... Jan 3, 2024
Z-1128-2018 Class II U2 Total Knee System Tibial Insert, Posterior S... Nov 24, 2017
Z-1692-2017 Class II UOC Femoral Driver, Product number PE 93045101,... Feb 10, 2017

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.